Taiwan · Delayed Price · Currency is TWD Welgene Biotech Statistics
Total Valuation
Welgene Biotech has a market cap or net worth of TWD 391.51 million. The enterprise value is 444.57 million.
| Market Cap | 391.51M |
| Enterprise Value | 444.57M |
Important Dates
The next estimated earnings date is Monday, August 24, 2026.
| Earnings Date | Aug 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Welgene Biotech has 23.30 million shares outstanding. The number of shares has increased by 1.49% in one year.
| Current Share Class | 23.30M |
| Shares Outstanding | 23.30M |
| Shares Change (YoY) | +1.49% |
| Shares Change (QoQ) | +5.01% |
| Owned by Insiders (%) | 10.49% |
| Owned by Institutions (%) | n/a |
| Float | 5.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.98 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 13.46 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.11 |
| EV / EBITDA | 20.35 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.91, with a Debt / Equity ratio of 0.90.
| Current Ratio | 1.91 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 11.44 |
| Debt / FCF | -2.44 |
| Interest Coverage | -0.53 |
Financial Efficiency
Return on equity (ROE) is -0.49% and return on invested capital (ROIC) is -0.80%.
| Return on Equity (ROE) | -0.49% |
| Return on Assets (ROA) | -0.26% |
| Return on Invested Capital (ROIC) | -0.80% |
| Return on Capital Employed (ROCE) | -0.50% |
| Weighted Average Cost of Capital (WACC) | 3.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.67 |
| Inventory Turnover | 4.79 |
Taxes
| Income Tax | -107,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.50% in the last 52 weeks. The beta is 0.20, so Welgene Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -21.50% |
| 50-Day Moving Average | 17.22 |
| 200-Day Moving Average | 18.47 |
| Relative Strength Index (RSI) | 43.12 |
| Average Volume (20 Days) | 5,811 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Welgene Biotech had revenue of TWD 398.92 million and -1.64 million in losses. Loss per share was -0.07.
| Revenue | 398.92M |
| Gross Profit | 166.87M |
| Operating Income | -2.49M |
| Pretax Income | -1.49M |
| Net Income | -1.64M |
| EBITDA | 15.19M |
| EBIT | -2.49M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 201.29 million in cash and 249.85 million in debt, with a net cash position of -48.56 million or -2.08 per share.
| Cash & Cash Equivalents | 201.29M |
| Total Debt | 249.85M |
| Net Cash | -48.56M |
| Net Cash Per Share | -2.08 |
| Equity (Book Value) | 277.63M |
| Book Value Per Share | 11.16 |
| Working Capital | 146.39M |
Cash Flow
In the last 12 months, operating cash flow was 29.09 million and capital expenditures -131.51 million, giving a free cash flow of -102.42 million.
| Operating Cash Flow | 29.09M |
| Capital Expenditures | -131.51M |
| Depreciation & Amortization | 17.67M |
| Net Borrowing | 85.46M |
| Free Cash Flow | -102.42M |
| FCF Per Share | -4.39 |
Margins
Gross margin is 41.83%, with operating and profit margins of -0.62% and -0.41%.
| Gross Margin | 41.83% |
| Operating Margin | -0.62% |
| Pretax Margin | -0.37% |
| Profit Margin | -0.41% |
| EBITDA Margin | 3.81% |
| EBIT Margin | -0.62% |
| FCF Margin | n/a |
Dividends & Yields
Welgene Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.49% |
| Shareholder Yield | -1.49% |
| Earnings Yield | -0.42% |
| FCF Yield | -26.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 17, 2018. It was a forward split with a ratio of 1.08.
| Last Split Date | Aug 17, 2018 |
| Split Type | Forward |
| Split Ratio | 1.08 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |